Basic & Clinical Medicine ›› 2025, Vol. 45 ›› Issue (6): 822-828.doi: 10.16352/j.issn.1001-6325.2025.06.0822
• Mini Reviews • Previous Articles Next Articles
SHI Lizhou, HAN Wei, SHEN Xiaojun*
Received:
2024-07-22
Revised:
2024-12-25
Online:
2025-06-05
Published:
2025-05-26
CLC Number:
SHI Lizhou, HAN Wei, SHEN Xiaojun. Role of nuclear poly(A) binding protein 1 in tumors[J]. Basic & Clinical Medicine, 2025, 45(6): 822-828.
[1] | Eliseeva IA, Lyabin DN, Ovchinnikov LP. Poly(A)-binding proteins: structure, domain organization, and activity regulation[J].Biochemistry (Mosc),2013,78:1377-1391. doi: 10.1134/S0006297913130014. |
[2] | 葛宏华.人源PABPN1 RRM结构域的结构生物学研究[D].合肥:中国科学技术大学,2008:20-21. |
[3] | Huang L, Li G, Du C, et al. The polyA tail facilitates splicing of last introns with weak 3' splice sites via PABPN1[J].EMBO Rep,2023,24:e57128. doi: 10.15252/embr.202357128. |
[4] | Eckmann CR, Rammelt C, Wahle E. Control of poly(A) tail length[J]. Wiley Interdiscip Rev RNA,2011,2:348-361. doi: 10.1002/wrna.56. |
[5] | Jenal M, Elkon R, Loayza-Puch F, et al. The poly(A)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites[J]. Cell,2012,149:538-553. doi: 10.1016/j.cell.2012.03.022. |
[6] | Apponi LH, Leung SW, Williams KR, et al.Loss of nuclear poly(A)-binding protein 1 causes defects in myogenesis and mRNA biogenesis[J]. Hum Mol Genet,2010,19:1058-1065. doi: 10.1093/hmg/ddp569. |
[7] | Beaulieu YB, Kleinman CL, Landry-Voyer AM, et al. Polyadenylation-dependent control of long noncoding RNA expression by the poly(A)-binding protein nuclear 1[J]. PLoS Genet,2012,8:e1003078. doi: 10.1371/journal.pgen.1003078. |
[8] | Ishigaki Y, Li X, Serin G, et al. Evidence for a pioneer round of mRNA translation: mRNAs subject to nonsense-mediated decay in mammalian cells are bound by CBP80 and CBP20[J]. Cell,2001,106:607-617. doi: 10.1016/s0092-8674(01)00475-5. |
[9] | Zhang Y, Liu L, Qiu Q, et al. Alternative polyadenyla-tion: methods, mechanism, function, and role in cancer[J]. J Exp Clin Cancer Res,2021,40:51. doi: 10.1186/s13046-021-01852-7. |
[10] | Curinha A, Oliveira Braz S, Pereira-Castro I, et al. Implications of polyadenylation in health and disease[J]. Nucleus,2014,5:508-519. doi: 10.4161/nucl.36360. |
[11] | Banerjee A, Apponi LH, Pavlath GK, et al. PABPN1: molecular function and muscle disease[J]. FEBS J,2013,280:4230-4250. doi: 10.1111/febs.12294. |
[12] | Xiang Y, Ye Y, Lou Y, et al. Comprehensive characterization of alternative polyadenylation in human cancer[J]. J Natl Cancer Inst,2018,110:379-389. doi: 10.1093/jnci/djx223. |
[13] | Hahn S, Nesslinger NJ, Drapala RJ,et al. Castration induces autoantibody and T cell responses that correlate with inferior outcomes in an androgen-dependent murine tumor model[J]. Int J Cancer,2009,125:2871-2878. doi: 10.1002/ijc.24673. |
[14] | Sáez-Martínez P, Porcel-Pastrana F, Montero-Hidalgo AJ, et al. Dysregulation of RNA-exosome machinery is directly linked to major cancer hallmarks in prostate cancer: Oncogenic role of PABPN1[J]. Cancer Lett,2024,584:216604. doi: 10.1016/j.canlet.2023.216604. |
[15] | Zhu D, Singh S, Chen X, et al. The landscape of chimeric RNAs in bladder urothelial carcinoma[J]. Int J Biochem Cell Biol,2019,110:50-58. doi: 10.1016/j.biocel.2019.02.007. |
[16] | Chen L, Dong W, Zhou M,et al. PABPN1 regulates mRNA alternative polyadenylation to inhibit bladder cancer progression[J]. Cell Biosci,2023,13:45. doi: 10.1186/s13578-023-00997-6. |
[17] | Xiong M, Liu C, Li W, et al. PABPN1 promotes clear cell renal cell carcinoma progression by suppressing the alternative polyadenylation of SGPL1 and CREG1[J]. Carcinogenesis,2023,44:576-586. doi: 10.1093/carcin/bgad049. |
[18] | 程波.舒尼替尼通过激活PABPN1/TRSM/AR/HIF-2α信号通路促进肾透明细胞癌血管拟态形成[D].广州:南方医科大学,2022:Ⅱ-Ⅲ. |
[19] | Wang L, Lang GT, Xue MZ, et al. Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers[J]. Theranostics,2020,10:10531-10547. doi: 10.7150/thno.40944. |
[20] | Fang F, Guo C, Zheng W, et al. Exosome-mediated transfer of miR-1323 from cancer-associated fibroblasts confers radioresistance of C33A cells by targeting PABPN1 and activating Wnt/β-catenin signaling pathway in cervical cancer[J]. Reprod Sci,2022,29:1809-1821. doi: 10.1007/s43032-021-00820-y. |
[21] | Ichinose J, Watanabe K, Sano A, et al. Alternative polyadenylation is associated with lower expression of PABPN1 and poor prognosis in non-small cell lung cancer[J]. Cancer Sci,2014,105:1135-1141. doi: 10.1111/cas.12472. |
[22] | Zhou L, Wu Y, Xin L,et al. Development of RNA binding proteins expression signature for prognosis prediction in gastric cancer patients[J]. Am J Transl Res,2020,12:6775-6792. |
[23] | 鄢雯, 李囡, 古同男, 等. 从GEO数据库筛选结肠癌差异关键基因及验证[J]. 基础医学与临床, 2023, 43: 1685-1692. |
[24] | Wang QH, Yan PC, Shi LZ, et al. PABPN1 functions as a predictive biomarker in colorectal carcinoma[J]. Mol Biol Rep,2023,51:40. doi: 10.1007/s11033-023-08936-x. |
[25] | Zhao A, Liu Y. Propofol suppresses colorectal cancer development by the circ-PABPN1/miR-638/SRSF1 axis[J].Anal Biochem,2021,631:114354. doi: 10.1016/j.ab.2021.114354. |
[26] | Zhen N, Zhu J, Mao S, et al. Alternative splicing of lncRNAs from SNHG family alters snoRNA expression and induces chemoresistance in hepatoblastoma[J].Cell Mol Gastroenterol Hepatol,2023,16:735-755. doi: 10.1016/j.jcmgh.2023.07.007. |
[27] | Ohshima K, Kanto K, Hatakeyama K, et al. Exosome-mediated extracellular release of polyadenylate-binding protein 1 in human metastatic duodenal cancer cells[J]. Proteomics,2014,14:2297-2306. doi: 10.1002/pmic.201300477. |
[28] | Kavoosi S, Shahraki A, Sheervalilou R. Identification of microRNA-mRNA regulatory networks with therapeu-tic values in Alzheimer's disease by bioinformatics analysis[J]. J Alzheimers Dis,2024,98:671-689. doi: 10.3233/JAD-230966. |
[29] | Zhang L, Wang D, Han X, et al. Novel read-through fusion transcript Bcl2l2-Pabpn1 in glioblastoma cells[J]. J Cell Mol Med,2022,26:4686-4697. doi: 10.1111/jcmm.17481. |
[1] | LUO Haojun, KONG Dexin, HUANG Wei, YANG Nan, LIU Yanyong. Construction of Hsp90-based fluorescent molecular probe and evaluation of pancreatic tumor recognition effects [J]. Basic & Clinical Medicine, 2025, 45(7): 905-911. |
[2] | GUO Anjing, CHEN Chong, LUO Yunping. A preliminary study on regulation of macrophages phenotype and anti-tumor effects by PRTN3 [J]. Basic & Clinical Medicine, 2025, 45(6): 701-708. |
[3] | CAO Jinjin, DU Juan, QU Shanna, ZHU Mingyu, WANG Yang, HU Han, LIU Binlei. Application of multi-targeted CAR-T cell therapy in B-cell acute lymphoblastic leukemia [J]. Basic & Clinical Medicine, 2025, 45(5): 675-680. |
[4] | LI Yunfan, ZOU Jiaming, WANG Yucheng, JU Rui, GUO Lei. CTO inhibits the in situ growth of glioblastoma in mice and regulates the metabolism and inflammatory phenotype of glioma-associated microglia [J]. Basic & Clinical Medicine, 2025, 45(4): 478-485. |
[5] | WANG Lining, LIU Honggang. The clinical pathological characteristics of malignant melanoma in nasal cavity and paranasal sinuses and its correlation with subsets of tumor infiltrating lymphocytes [J]. Basic & Clinical Medicine, 2025, 45(4): 527-531. |
[6] | ZHANG Dakun, ZHANG Hongbo, DONG Dexin, GAO Xiang, MENG Qiang, GAO Jiyuan. Clinical characteristics of renal epithelioid angiomyolipoma [J]. Basic & Clinical Medicine, 2025, 45(3): 375-377. |
[7] | LOU Haijun, MENG Menggen, ZHANG Zhenyu, TONG Zhuoyun, WUDU Muli. Role of transmembrane protein 33 in tumorigenesis and development [J]. Basic & Clinical Medicine, 2025, 45(2): 258-262. |
[8] | XIA Yujia, YANG Zhenli, LIU Yuqin. Preclinical translational research and application of tumor organoids [J]. Basic & Clinical Medicine, 2024, 44(9): 1214-1218. |
[9] | LIU Baoqing, HUANG Rong, LU Yan, LI Kai, ZHANG Ning, LIU Changzheng, SONG Wei. Progress of gastric cancer organoids in basic research and clinical application [J]. Basic & Clinical Medicine, 2024, 44(9): 1219-1222. |
[10] | LI Yang, ZHU Lei. Eukaryotic elongation factor 2 kinase is a potential new target for the treatment of tumors [J]. Basic & Clinical Medicine, 2024, 44(7): 1039-1043. |
[11] | CHEN Xiaotian, CHEN Chong, LUO Yunping. Impact of MAFB on polarization and function of tumor associated macrophages [J]. Basic & Clinical Medicine, 2024, 44(7): 965-973. |
[12] | ZHOU Yue, TONG Anli. Immune microenvironment of pheochromocytomas and paragangliomas [J]. Basic & Clinical Medicine, 2024, 44(6): 742-747. |
[13] | ZHANG Liyuan, DU Hanze, PAN Hui. Progress in drug therapy for hypothalamic obesity [J]. Basic & Clinical Medicine, 2024, 44(5): 729-732. |
[14] | WANG Tingting, GUO Dan, LU Junyang, XU Lai, DONG Haitao, LIN Dianxin, XIAO Yi. Analysis of cell mutation types of colorectal neuroendocrine tumors [J]. Basic & Clinical Medicine, 2024, 44(4): 523-527. |
[15] | LEI Shaoyuan, LI Yulong, SUN Fei, LIU Hongjun, WU Yue, GUO Yansu. The epidemiology and prediction of brain tumors incidence and mortality in China [J]. Basic & Clinical Medicine, 2024, 44(4): 454-458. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||
Full text 24
|
|
|||||||||||||||||||||||||||||||||||||||||||||
Abstract 46
|
|
|||||||||||||||||||||||||||||||||||||||||||||